title: Surgery for distant melanoma metastasis.
abstract: Traditionally, distant metastatic melanoma has a poor prognosis owing to lack of efficacious, U.S. Food and Drug Administration-approved systemic therapy and the limited use of surgical resection as a therapeutic option. More recently, new biological therapies such as vemurafenib (Zelboraf) and ipilimumab (Yervoy) have shown strong promise and dramatically improved the landscape of stage IV melanoma therapy. Although there are numerous single-institution studies advocating the role for therapeutic surgical intervention, many remain skeptical of nonpalliative surgery for metastatic melanoma. Surgical resection of advanced melanoma has been proven to be effective as long as all disease is removed (R0). Patient selection is paramount. The combination of newer systemic therapies and surgical resection is currently under investigation. Understanding the tumor biology of melanoma and its mechanism of metastatic spread is essential to developing the most efficacious treatment strategy.
authors.affiliation: Department of Surgical Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA 90404, USA.
authors.forename: Anna M
authors.initials: AM
authors.lastname: Leung
authors.forename: Danielle M
authors.initials: DM
authors.lastname: Hari
authors.forename: Donald L
authors.initials: DL
authors.lastname: Morton
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D008545:Melanoma / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D009367:Neoplasm Staging; D012008:Recurrence; D016019:Survival Analysis